Benefits of Early ASCT for Newly Diagnosed Multiple Myeloma (MM) and the Incidence of Second Primary Cancer with Lenalidomide Maintenance in the Treatment of MM
Boccadoro M et al. Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) in newly diagnosed multiple myeloma (MM) patients: A phase III trial. Proc ASCO 2011;Abstract 8020.
Dr Giralt is Chief of the Adult Bone Marrow Transplant Service at Memorial Sloan-Kettering Cancer Center in New York, New York.
|